CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026
CAMP4 Therapeutics will host a virtual Analyst Day on September 28, 2026, to discuss its clinical-stage pipeline and the design of its first-in-human Phase 1/2 trial of CMP-002. The event will feature presentations from executive leadership and patient advocates, including a keynote from KOL Stéphane Auvin.
Key figures
- Date
- September 28, 2026
- Time
- 12:00 – 1:30 PM ET
- Trial phase
- Phase 1/2
- Trial start
- Q4 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.